ArticleBMC complementary medicine and therapies2026
Herbal preparations traditionally used in upper respiratory tract infections: UHPLC-DAD-ESI-MS/MS
Article in BMC complementary medicine and therapies, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Upper respiratory tract infections (URTIs) constitute a major global health concern, accounting for a substantial proportion of primary care visits and pharmaceutical consultations each year. Clinically, URTIs manifest with symptoms such as rhinitis, pharyngitis, laryngitis, cough, and fever, with considerable variability in severity and duration. In light of the limitations associated with conventional treatment strategies and the growing threat of antibiotic resistance, plant-based preparations have attracted increasing scientific interest as complementary therapeutic approaches. However, despite a long tradition of use, comprehensive studies integrating detailed phytochemical characterisation with functional assessment of their immunomodulatory effects on human innate immune cells remain limited.The present study aimed to characterise the phytochemical composition and evaluate the anti-inflammatory potential of aqueous and ethanolic extracts derived from ten medicinal plants traditionally used in the treatment of URTIs. Extracts were profiled by UHPLC-DAD-ESI–MS/MSn and evaluated for biological activity using human PBMC-derived monocytes/macrophages and neutrophils isolated from healthy donors as in vitro models of innate immune response. The anti-inflammatory activity was evaluated by quantifying pro-inflammatory cytokine secretion (TNF-α, IL-1β, IL-6, IL-8), reactive oxygen species (ROS) generation, and surface expression of β₂ integrins (Mac-1, LFA-1).Phytochemical profiling revealed marked differences in the composition of aqueous (infusion) and ethanolic (tincture) extracts, reflecting the influence of the extraction solvent on the selective enrichment of distinct compound classes. These compositional differences translated into distinct biological activity profiles, with individual extracts exhibiting differential potency and cell-type specificity.Collectively, these findings provide a scientific rationale for the traditional use of the investigated plant species in the management of URTIs and highlight their potential as evidence-based complementary interventions modulating the innate immune response. The observed cell-type selectivity and differential potency of the tested preparations warrant further investigation to identify the key bioactive constituents responsible for the reported effects and to elucidate their precise molecular mechanisms of action.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.